Clinical Trials Logo

Recurrent Glioblastoma clinical trials

View clinical trials related to Recurrent Glioblastoma.

Filter by:

NCT ID: NCT03573986 Recruiting - Clinical trials for Recurrent Glioblastoma

Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment

Start date: April 18, 2018
Phase: Phase 1
Study type: Interventional

Subjects with recurrent glioblastoma who are candidates for bevacizumab treatment according to standard of care will be eligible for this study. Positron emission tomography (PET/CT) imaging will use the investigational radiotracer [18F]FMISO to image the brain and evaluate for hypoxia pre and post therapy.. Subjects will also undergo up to three Brain MRIs.

NCT ID: NCT03557372 Not yet recruiting - Clinical trials for Recurrent Glioblastoma

Mathematical Model-Adapted Radiation In Glioblastoma

Start date: June 2018
Phase: N/A
Study type: Interventional

This research study is studying a new schedule of radiation therapy for recurrent glioblastoma as a possible treatment for this diagnosis. This radiation schedule is based on a new model for radiation resistance in glioblastoma. The name of the radiation schedule involved in this study is: - Re-irradiation for glioblastoma using a novel Mathematical Model-Adapted Radiation Fractionation Schedule

NCT ID: NCT03539731 Recruiting - Clinical trials for Recurrent Glioblastoma

[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

Start date: April 23, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies how well [18F]DASA-23 and positron emission tomography (PET) scan work in evaluating pyruvate kinase M2 (PKM2) expression in patients with intracranial tumors or recurrent glioblastoma and healthy volunteers. PKM2 regulates brain tumor metabolism, a key factor in glioblastoma growth. [18F]DASA-23 is a radioactive substance with the ability to monitor PKM2 activity. A PET scan is a procedure in which a small amount of a radioactive substance, such as [18F]DASA-23, is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the substance is used. Tumor cells usually pick up more of these radioactive substances, allowing them to be found. Giving [18F]DASA-23 with a PET scan may help doctors evaluate PKM2 expression in healthy volunteers and in participants with intracranial tumors or recurrent glioblastoma.

NCT ID: NCT03430791 Not yet recruiting - Clinical trials for Recurrent Glioblastoma

Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-naïve, Recurrent Glioblastoma

Start date: August 2018
Phase: Phase 2
Study type: Interventional

Phase II trial in which participants with bevacizumab-naïve, recurrent glioblastoma will receive a combination of tumor treating fields(portable device), nivolumab with or without ipilimumab.

NCT ID: NCT03392545 Not yet recruiting - Clinical trials for Recurrent Glioblastoma

Combination of Immunization and Radiotherapy for Recurrent GBM (InSituVac1)

InSituVac1
Start date: July 1, 2018
Phase: Phase 1
Study type: Interventional

The study will investigate combined radiotherapy and immunotherapy on recurrent glioblastoma(GBM). Immune adjuvants will be injected intratumorally and systemically to induce antitumor-specific immunity after radiation induced immunological tumor cell death (ICD). With radiation, tumor cells release tumor antigens that are captured by antigen presenting dendritic cells. Immune adjuvants promote the presentation of tumor antigens and the priming of antitumor T lymphocytes. The combined treatment induces and amplifies the specific antitumor immunity in recurrent GBM patients, prolonging survivals for GBM patients.

NCT ID: NCT03360708 Not yet recruiting - Clinical trials for Recurrent Glioblastoma

Vaccine Therapy and Cytokine-Induced Killer Cells in Treating Patients With Recurrent Glioblastoma

Start date: November 30, 2018
Phase: Early Phase 1
Study type: Interventional

This pilot early phase I trial studies the side effects of vaccine therapy and cytokine-induced killer cells in treating patients with glioblastoma that has come back. Vaccines made from a person's white blood cells mixed with tumor proteins from another person's glioblastoma tumors may help the body build an effective immune response to kill tumor cells. Cytokine-induced killer cells are white blood cells with a powerful ability to kill tumor cells without any further modification. Giving vaccine therapy and cytokine-induced killer cells may work better in treating patients with glioblastoma.

NCT ID: NCT03283631 Recruiting - Clinical trials for Recurrent Glioblastoma

Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM

INTERCEPT
Start date: May 30, 2018
Phase: Phase 1
Study type: Interventional

Malignant primary brain tumors account for more human deaths than melanoma or cancer of the bladder or kidney. The non-specific nature of conventional therapy for brain tumors often results in incapacitating damage to surrounding normal brain and systemic tissue. Thus, in order to reduce off-site effects and be more effective, therapeutic strategies will have to target tumor cells precisely while minimizing collateral damage to the neighboring cerebral cortex. The goal of this protocol is to transfer autologous peripheral blood mononuclear cells (PBMCs) transduced with genes encoding a chimeric antigen receptor (CAR) that recognizes epidermal growth factor receptor variant III (EGFRvIII) tumor-specific antigen into patients with recurrent glioblastoma multiforme (GBM) following stereotactic radiosurgery (SRS). The CAR used will be targeted to a tumor-specific mutation of the epidermal growth factor receptor, EGFRvIII, which is expressed on a subset of patients. Normal PBMCs derived from patients with GBM will be genetically engineered with a viral vector encoding the CAR and infused directly into the patient's tumor with the aim of mediating regression of their tumors. Despite our CAR being targeted to a tumor specific antigen, given the prior toxicity using CARs that were not targeted to tumor-specific antigens, the investigators have elected to begin with very low doses of cells.

NCT ID: NCT03275558 Not yet recruiting - Gliosarcoma Clinical Trials

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Start date: February 2018
Phase: Phase 1
Study type: Interventional

This is a study to determine the efficacy, safety and clinical benefit (how well the drugs works), of the pharmaceutical compositions in Nasal Spray NST-4G for the treatment of brain tumors( Recurrent Glioblastoma, Gliosarcoma,Anaplastic Gliomas, Previously Treated). All drugs target the inhibition of the growth factors and neo-angiogenesis as one the main reasons for the growth of the tumor. The purpose of the Nasal Spray NST-4G study is to determine the safety and tolerability in order to establish the best dose level to be used in future studies.

NCT ID: NCT03216499 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma

PT2385
Start date: August 15, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well HIF-2 alpha inhibitor PT2385 works in treating patients with recurrent glioblastoma. HIF-2 alpha inhibitor PT2385 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03115333 Recruiting - Gliosarcoma Clinical Trials

DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Start date: April 14, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient?s response to treatment.